Login / Signup

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.

Sukhmani K PaddaKaren L ReckampMarianna KoczywasJoel W NealJun KawashimaShengchun KongDaniel B HuangMark KowalskiHeather A Wakelee
Published in: Cancer chemotherapy and pharmacology (2021)
NCT02206763.
Keyphrases
  • small cell lung cancer
  • epidermal growth factor receptor
  • squamous cell carcinoma
  • tyrosine kinase
  • hiv infected
  • advanced non small cell lung cancer
  • antiretroviral therapy
  • smoking cessation